Changeflow GovPing Pharma & Drug Safety EphA2-binding Peptide and Composition Patent Ap...
Routine Rule Added Final

EphA2-binding Peptide and Composition Patent Application

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.

What changed

The USPTO published a patent application for an EphA2-binding peptide composition, covering peptides that bind to the Eph receptor A2 and compositions comprising such peptides. The application includes 13 inventors and carries CPC classifications indicating peptide chemistry and pharmaceutical composition technologies.

Affected parties including pharmaceutical companies, biotech researchers, and drug developers should monitor this pending patent application as it may affect therapeutic peptide development targeting EphA2-related applications. The composition claims could impact R&D programs in targeted therapy and oncology research areas.

What to do next

  1. Monitor patent prosecution status for potential infringement implications
  2. Review composition claims for R&D and product development alignment

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME

Application US20260098061A1 Kind: A1 Apr 09, 2026

Inventors

Takanori Aoki, Takeru Ehara, Sora Enya, Makoto Jitsuoka, Kouki Morimoto, Shunichi Nakano, Takayuki Nagasawa, Masaki Ohuchi, Hayato Yanagida, Zaid Amso, Rongjun He, Derek Cole

Abstract

The present technology generally relates to peptides that bind to the Eph receptor A2 (EphA2), to peptides that bind to the EphA2, and to compositions comprising such peptides.

CPC Classifications

C07K 7/64 A61K 47/64

Filing Date

2023-09-28

Application No.

19115394

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
US20260098061A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Research institutions
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent applications Biotherapeutic development Drug composition research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!